Should we discontinue angiotensin converting enzyme inhibitor and angiotensin receptor blocker before kidney transplantation?

Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?

Chronic kidney disease (CKD) is a worldwide public health problem associated with a high prevalence of cardiovascular disease (CVD) and impaired quality of life. Previous research for preventing loss of glomerular filtration rate (GFR) has focused on reducing blood pressure (BP) and proteinuria. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (ARB) are co...

Angiotensin Converting Enzyme in Sarcoidosis

Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation

Both angiotensin-receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) have protective effects against atrial fibrillation (AF). The differences between ARB and ACEI in their effects on the primary prevention of AF remain unclear. This study compared ARB and ACEI in combined antihypertensive medications for reducing the risk of AF in patients with hypertension, and determi...

Effects of Angiotensin Converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker

Background. The degree of cardiac hypertrophy is not only load dependent: Among other factors, the renin-angiotensin system may play a role in the regulation of cardiac myocyte growth. Methods and Results. To evaluate the role of the renin-angiotensin system in volume overload-induced cardiac hypertrophy, we assessed 1) the time course of changes in cardiac hemodynamics, cardiac anatomy, and pl...

Review: Angiotensin II receptor blocker plus angiotensin-converting enzyme inhibitor increases risk for adverse effects.

M e t h o d s Data sources: MEDLINE and EMBASE/ Excerpta Medica (to December 2006), Cochrane Library, National Institutes of Health Clinical Trials and US Food and Drug Administration Web sites, and reference lists. Study selection and assessment: Randomized controlled trials (RCTs) with ≥ 500 patients that compared the combination of ARB and ACE-I with standard therapy that included ACE-I for ...